AstraZeneca director Jorge Mazzei said on Monday that he believes Brazil will get the coronavirus vaccine developed by the Oxford University by the end of this year if the experimental jab proves successful.
Oxford-AstraZeneca’s vaccine ChAdOx1 nCoV-19 made from a weakened and non-replicating version of a common cold virus (adenovirus) and has been engineered to express the SARS-CoV-2 spike protein is one of the most promising candidates against COVID-19.
The vaccine is being tested on more than 5,000 health care workers in Brazil since last week. It may be noted that on 2nd June, Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials being conducted in partnership with AstraZeneca.
Apart from Oxford, China National Biotec Group (CNBG) has also started phase 3 clinical trials of its inactivated COVID-19 vaccine candidate in the United Arab Emirates.
On Monday, Mazzei told reporters that the South American nation is close to a dea
Oxford-AstraZeneca’s vaccine ChAdOx1 nCoV-19 made from a weakened and non-replicating version of a common cold virus (adenovirus) and has been engineered to express the SARS-CoV-2 spike protein is one of the most promising candidates against COVID-19.
The vaccine is being tested on more than 5,000 health care workers in Brazil since last week. It may be noted that on 2nd June, Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials being conducted in partnership with AstraZeneca.
Apart from Oxford, China National Biotec Group (CNBG) has also started phase 3 clinical trials of its inactivated COVID-19 vaccine candidate in the United Arab Emirates.
On Monday, Mazzei told reporters that the South American nation is close to a dea
Category
🦄
Creativity